dMMR

  • June 13, 2022  

    ‘Unprecedented’ 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly Bookmark

    George Lundberg, MD

    In a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.

    .

  • June 10, 2022  

    Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer Bookmark

    George Lundberg, MD

    This 2022 scientific review article from the Journal of the Advanced Practitioner in Oncology discusses new treatment options for people with advanced endometrial cancer.

    .